Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2165 • 2012 ACR/ARHP Annual Meeting
Utility of Vectra-DA™ On Assessment of Rheumatoid Arthritis Disease Activity and Golimumab Response: Results of a Pilot Study From a Phase 3 Trial in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
Sarah Lamberth, Yauheniya Cherkas, Carrie Brodmerkel and Mark Curran, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: Currently, disease activity in Rheumatoid Arthritis (RA) is measured using scoring systems that rely primarily on a collection of subjective measures from patients and…
Abstract Number: 1693 • 2012 ACR/ARHP Annual Meeting
Oncogenic Activation of MAPK in Rheumatoid Arthritis Synovial Fibroblasts
Niloofar L. Farmani¹, Keith K. Colburn², Grace Chan³, Erica Li³, Emil Heinze⁴, Antonia Rubell³, Robert Nishimura⁵ and Richard H. Weisbart³, ¹Medicine, Olive View-UCLA Medical Center, Sylmar, CA, ²Dept Med - Rheum Sect, Loma Linda Univ Medical Center, Loma Linda, CA, ³Research, VAGLAHS, Sepulveda, CA, ⁴Rheumatology, Olive View-UCLA Medical Center, Sylmar, CA, ⁵Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Transformed synovial fibroblasts (SF) mediate joint-specific damage in rheumatoid arthritis (RA) by expressing integrins and metalloproteinase that promote adhesion to and invasion of cartilage.…
Abstract Number: 865 • 2012 ACR/ARHP Annual Meeting
A Methodology for Estimating Disease State Transitions: Repeated Measures Markov Models with Covariate Dependence
George W. Reed¹, Andrew S. Koenig², Katherine C. Saunders³, David H. Collier⁴, Joel M. Kremer⁵ and Sameer Kotak⁶, ¹University of Massachusetts Medical School, Worcester, MA, ²Specialty Care, Pfizer Inc, Collegeville, PA, ³Corrona, LLC., Southborough, MA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Many RA patients have variable disease activity over time due to disease flare, reduction in efficacy of current medications and other disease mediating…
Abstract Number: 385 • 2012 ACR/ARHP Annual Meeting
The Wide Variation in Corticosteroid Use in Early Rheumatoid Arthritis – There Is Need for Guidelines
A. Bharadwaj¹ and Carol Alves², ¹Rheumatology, Basildon & Thurrock University Hospital NHS Trust, Basildon, United Kingdom, ²Research & Development, Basildon & Thurrock University Hospital NHS Trust, Basildon, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease which causes significant pain and swelling in the joints. The early treatment of the disease mainly…
Abstract Number: 58 • 2012 ACR/ARHP Annual Meeting
5 Million Patients and Not 0.34% Is Worrisome: Burden of Rheumatoid Arthritis in India Based On a Bone and Joint Decade India Community Oriented Program for Control of Rheumatic Disease
Arvind Chopra¹, R. Ghorpade², S. Sarmukkadam³, VL Joshi¹, AJ. Mathews⁴, L. Gauri⁵, A. Rahim⁶, K. Datta⁷, S. Chaturvedi⁸, B. Thakuria⁹, A. Mahajan¹⁰, R. Singh¹¹, A. Ghosh¹², R. Handa¹³, Manjit Saluja¹⁴, A. Venugopalan¹, V. Kunjeer¹, B. Paul⁶, S. Pal⁷, K. Wangjam¹¹, T. Kumar¹⁵ and K. Mahendranath¹⁶, ¹Rheumatology, Center for Rheumatic Diseases, Pune, India, ²Center for Rheumatic Diseases, Pune, India, ³BJMC, Pune, India, ⁴Government Medical College Hospital, Trivandrum, India, ⁵SP Medical College, Bikaner, India, ⁶Calicut Medical College, Calicut, India, ⁷Advance Rheumatology Clinic, Hyderabad, India, ⁸FRCH, Pune, India, ⁹Guwahati Medical College & Hospital, Guwahati, India, ¹⁰Government Medical College, Jammu, India, ¹¹Regional Institute of Medical Sciences, Imphal, Manipur, India, ¹²Rheumatology, Institute of Post Graduate Medical Education and Research, Kolkata, India, ¹³Department of Rheumatology, AIIMS, New Delhi, India, ¹⁴Clinical care, Center for Rheumatic Diseases, Pune, India, ¹⁵Institute of Post Graduate Medical Education and Research, Kolkata, India, ¹⁶Rheumatology Clinic, Bangalore, India
Background/Purpose : The 1 % prevalence of RA Worldwide is a deep rooted ancient dogma. None of the recent WHO ILAR COPCORD (Community Oriented Program…
Abstract Number: 2147 • 2012 ACR/ARHP Annual Meeting
Risks to Visit Emergency Room in Patients with Rheumatoid Arthritis: A Two-Year Retrospective Study
Yoshiki Nagai, Naoto Yokogawa, Kota Shimada and Shoji Sugii, Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) suffer from both physical disabilities and medical comorbidities and tend to use emergency room for many reasons. However, the…
Abstract Number: 1626 • 2012 ACR/ARHP Annual Meeting
Frequent Conversion of Tuberculosis Screening Tests During Anti-Tumor Necrosis Factor Therapy in Patients with Rheumatic Diseases
Chrisoula Hatzara¹, Emilia Hadziyannis², Anna Kandili¹, Stamatoula Tsikrika¹, Martha Minopetrou¹, Georgios Georgiopoulos¹ and Dimitrios Vassilopoulos¹, ¹2nd Department of Medicine, Athens University School of Medicine, Athens, Greece, ²2nd Department of Medicine and Laboratory of Clinical Immunology-Rheumatology, Hippokration General Hospital, University of Athens Medical School, Athens, Greece
Background/Purpose: The most recent ACR Recommendations suggest annual screening for latent tuberculosis (TB) with standard tuberculin skin test (TST) or the newer interferon-gamma release assays…
Abstract Number: 808 • 2012 ACR/ARHP Annual Meeting
Power Doppler Is Predictive of Treatment Failure in Early Rheumatoid Arthritis Patients: A One Year Follow-up Study
Karine R. Luz¹, Rita N.V. Furtado¹, Marcelo M. Pinheiro², Giovanna S. Petterle¹ and Jamil Natour¹, ¹Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ²Brazilian Registry of Spondyloarthritis, São Paulo, Brazil
Background/Purpose: It is known that ultrasound (US) is a useful test to monitor rheumatoid arthritis (RA) patients. However, to date, no study has shown the…
Abstract Number: 351 • 2012 ACR/ARHP Annual Meeting
Prospective Follow-up of Tocilizumab Treatment in 764 Patients with Refractory Rheumatoid Arthritis: Tolerance and Efficacy Data From the French Registry Regate (REGistry –RoAcTEmra)
Jacques Morel¹, Marie-Odile Duzanski², Thomas Bardin³, Alain G. Cantagrel⁴, Bernard Combe⁵, Maxime Dougados⁶, Rene-Marc Flipo⁷, Jacques-Eric Gottenberg⁸, Xavier Mariette⁹, Martin Soubrier¹⁰, Olivier Vittecoq¹¹, Alain Saraux¹², Thierry Schaeverbeke¹³ and Jean Sibilia¹⁴, ¹Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ²Service Pharmacie - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³Rheumatology, Hôpital Lariboisière, Paris, France, ⁴Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁵Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁶Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁷Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁸Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹⁰Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ¹¹Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ¹²Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ¹³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rhumatologie, CHU Hautepierre, Strasbourg, France
Background/Purpose: To assess tolerance and safety of rheumatoid arthritis (RA) treatment by tocilizumab (TCZ) in real life Methods: The French Society of Rheumatology and the…
Abstract Number: 2152 • 2012 ACR/ARHP Annual Meeting
Inhibition of Fucose Incorporation Abrogates the Development of Arthritis by Suppressing the Inflammatory Macrophage Development and TNF-α Production
Jun Li¹, Hui-Chen Hsu², PingAr Yang¹, Qi Wu¹, David M. Spalding³, W. Winn Chatham⁴, Robert P. Kimberly⁵, S. Louis Bridges Jr.⁶ and John D. Mountz⁷, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Clinical Immunology & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁷Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL
Background/Purpose: Fucosylation, catalyzed by fucosyltransferases (Futs), is an important glycosylation process involved in inflammation, cell death, and differentiation. We have observed an extremely high positive correlation…
Abstract Number: 1584 • 2012 ACR/ARHP Annual Meeting
Validity of the Nurses Health Study II Physical Activity Questionnaire (NHSPAQ) in Estimating Physical Activity in Adults with Rheumatoid Arthritis (RA)
Maura D. Iversen¹, Thomas Quinn² and Michelle A. Frits³, ¹Department of Physical Therapy, Movement & Rehabilitation Sciences, Northeastern University, Boston, MA, ²Biology, Northeastern University, Boston, MA, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: An accurate assessment of physical activity (PA) is critical to manage rheumatoid arthritis (RA). Accelerometry is an objective measure of PA but is not…
Abstract Number: 652 • 2012 ACR/ARHP Annual Meeting
Serum Rituximab Levels and Efficiency of B-Cell Depletion: Differences Between Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Venkat Reddy¹, Sara Croca², Delia Gerona³, Inmaculada De La Torre Ortega³, David A. Isenberg⁴, Maria Leandro² and Geraldine Cambridge⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ⁴Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Variability in rituximab-induced B-cell depletion (BCD) occurs in a significant number of patients with Systemic Lupus Erythematosus (SLE) and to a lesser extent in…
Abstract Number: 352 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis
Charlotte Hua¹, Thomas Barnetche², Bernard Combe³ and Jacques Morel⁴, ¹Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Vaccines against influenza and streptococcus pneumonia are currently recommended for patients with rheumatoid arthritis (RA). This meta-analysis assesses current literature data on the impact…
Abstract Number: 2665 • 2012 ACR/ARHP Annual Meeting
Metabolic Reprogramming of Autoimmune T Cells in Rheumatoid Arthritis
Zhen Yang¹, Hiroshi Fujii², Shalini Mohan¹, Jorg J. Goronzy¹ and Cornelia M. Weyand³, ¹Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ³Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: In RA, autoimmunity precedes clinical symptoms by a decade and persists unabated even when downstream inflammation is well controlled; exposing lymphocytes to chronic stimulation…
Abstract Number: 2129 • 2012 ACR/ARHP Annual Meeting
Dickkopf-1 Is Increased in Rheumatoid Arthritis of Recent Onset and Might Be a New Biomarker of Structural Progression. Data From the Espoir Cohort
Raphaèle Seror¹, Stephan Pavy², Thierry Schaeverbeke³, Alain Saraux⁴, Xavier Mariette⁵ and Corinne Miceli-Richard¹, ¹Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ²Hopital Bicetre, Paris, France, ³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁴Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ⁵Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Dickkopf-1 (DKK-1) is an inhibitory protein of the Wnt signalling pathway that could be involved in subchondral bone erosions occurring in rheumatoid arthritis (RA).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].